Fig. 1.
Participants reporting PAEs by treatment week for major subtopics of anxiety, depression, and sleep disorders. Data are presented as percent of participants reporting PAEs for each subtopic. The total number of NB or placebo patients reporting PAEs for each subtopic are listed below each bar. NB, 32 mg naltrexone PR plus 360 mg bupropion PR (or 32 mg naltrexone immediate release plus 400 mg bupropion PR in study NB-201); PAE psychiatric adverse event, PR prolonged release